<DOC>
	<DOCNO>NCT00616499</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes need cell growth . Giving Gefitinib surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well gefitinib work treat patient stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Gefitinib Treating Patients With Stage IIIA Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess response rate gefitinib treatment preoperative induction therapy patient biopsy-proven stage IIIA ( pN2 ) non-squamous non-small cell lung cancer accompany epidermal growth factor receptor ( EGFR ) mutation . Secondary - To determine complete resection rate patient treat drug . - To determine overall survival rate patient treat drug . - To determine disease-free survival rate patient treat drug . - To determine pathologic complete response rate patient treat drug . - To determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive oral gefitinib day day 1-28 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient resectable disease may undergo surgery . Patients unresectable disease may undergo surgery , chemotherapy , and/or radiotherapy . After completion study therapy , patient follow 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven stage IIIA nonsquamous nonsmall cell lung cancer pN2 disease proven mediastinoscopy Meets follow criterion : Never smoke EGFR mutation ( exon 18 , 19 , 21 ) * FISH positive EGFR* NOTE : *Irrespective smoking history Presence least 1 unidimensionally measurable lesion thoracic CT scan , accord RECIST Feasible undergo pneumonectomy lobectomy PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 01 FEV_1 ≥ 2.0 L preoperative pulmonary function test Hemoglobin ≥ 9.0 g/dL WBC 4,00012,000/μL ANC ≥ 1,500/μL Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3.0 time ULN AST ALT ≤ 3.0 time ULN Creatinine ≤ 1.5 time ULN Negative pregnancy test Exclusion criterion : Severe complication infection Pregnant breastfeed woman Clinically significant heart disease Uncontrolled hepatitis , chronic liver disease , diabetes mellitus Another active cancer except properly treat carcinoma situ cervix basal/squamous cell skin carcinoma PRIOR CONCURRENT THERAPY : No prior radiotherapy , chemotherapy , hormone therapy , target therapy No concurrent systemic anticancer therapy , include experimental drug , chemotherapy , immunotherapy , radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
</DOC>